NBS-C  BioScience 
Immunogenicity Studies 

Unwanted immune reactions inducing anti-drug antibodies (ADA) may neutralize drug efficacy or cause allergic reactions and other severe side effects, representing a major issue in the development of therapeutic proteins.

Proteins developed as vaccines have to be designed, manufactured and formulated to induce the best protective immune response possible, directed primarily against specific epitopes and not against non relevant portions like protein scaffolds or carrier molecules.

 NBS-C BioScience offers assistance in drug selection and development of biologics and vaccines by carrying out immunogenicity studies. Besides standard ELISA procedures Surface Plasmon Resonance (SPR; Biacore) is applied which allows extended ADA tracking and vaccine profiling. NBS-C BioScience also develops functional (cell-based) assays to assess formation of neutralizing antibodies.